Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabergoline for treatment of uterine myoma
IRCT20170917036227N4Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Fibromyoma (LM) comparing Cabergoline with Placebo (2 arms). Primary endpoints: Uterine bleeding, Size of leiomyoma and 1 more. Started Apr 2019; status: completed.
02
Drugs
cabergoline
03
Conditions
Fibromyoma (LM)
Beyond the preview
Go deeper on IRCT20170917036227N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20170917036227N4.